依达拉奉对脂多糖诱导的大鼠多巴胺能神经元变性保护作用的研究

被引:3
作者
徐芳 [1 ]
任士卿 [1 ]
王彦永 [2 ]
刘俊艳 [1 ]
机构
[1] 河北医科大学第三医院神经内科
[2] 河北省脑老化与认知神经科学实验室
关键词
依达拉奉; 脂多糖; 小胶质细胞; 帕金森病; 大鼠;
D O I
暂无
中图分类号
R742.5 [震颤麻痹综合征];
学科分类号
摘要
目的探讨自由基清除剂依达拉奉对脂多糖(LPS)诱导的多巴胺能神经元变性的保护作用。方法18只大鼠随机分成3组:磷酸缓冲液(PBS)对照组、生理盐水+LPS组(生理盐水治疗组)和依达拉奉+LPS组(依达拉奉治疗组)。黑质内立体定向注射15μg(2μl)LPS或PBS,采用免疫组织化学方法观察注射后14d大鼠黑质酪氨酸羟化酶(TH)阳性细胞的数量以及小胶质细胞的形态学变化。结果与对照组相比,生理盐水治疗组TH阳性细胞数减少到对侧的16%(P<0.05),细胞突触也明显减少;依达拉奉治疗组TH阳性细胞数较生理盐水治疗组明显增多,为对侧的59%(P<0.05),部分突触存在。两治疗组小胶质细胞形态无明显差异。结论依达拉奉显著抑制LPS诱导的黑质多巴胺能神经元变性。
引用
收藏
页码:64 / 67
页数:4
相关论文
共 7 条
[1]  
Protective effect of the radical scavenger edaravone against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum[J] . Toshiyuki Kawasaki,Kotaro Ishihara,Yukio Ago,Shigeo Nakamura,Soichi Itoh,Akemichi Baba,Toshio Matsuda.European Journal of Pharmacology . 2006 (1)
[2]   Edaravone protects PC12 cells from ischemic-like injury via attenuating the damage to mitochondria. [J].
Song Y. ;
Li M. ;
Li J.C. ;
Wei E.Q. .
Journal of Zhejiang University SCIENCE B, 2006, 7 (9) :749-756
[3]  
Reactive Macrophages Increase Oxidative Stress and Alpha-Synuclein Nitration During Death of Dopaminergic Neuronal Cells in Co-Culture: Relevance to Parkinson’s Disease[J] . Shaik Shavali,Colin K. Combs,Manuchair Ebadi.Neurochemical Research . 2006 (1)
[4]  
Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism[J] . Michelle L. Block,Jau-Shyong Hong.Progress in Neurobiology . 2005 (2)
[5]   Inflammatory process as a determinant factor for the degeneration of substantia nigra dopaminergic neurons [J].
Herrera, AJ ;
Tomás-Camardiel, M ;
Venero, JL ;
Cano, J ;
Machado, A .
JOURNAL OF NEURAL TRANSMISSION, 2005, 112 (01) :111-119
[6]  
Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-α, interleukin-1β, and nitric oxide[J] . Dave A Gayle,ZaoDung Ling,ChongWai Tong,Teresa Landers,Jack W Lipton,Paul M Carvey.Developmental Brain Research . 2002 (1)
[7]  
NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. Wu DC, Teismann P, Tieu K, et al. Proceedings of the National Academy of Sciences of the United States of America . 2003